

# Whitney B Pope

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9480834/publications.pdf>

Version: 2024-02-01

167  
papers

10,434  
citations

29994

54  
h-index

34900

98  
g-index

167  
all docs

167  
docs citations

167  
times ranked

10833  
citing authors

#	ARTICLE	IF	CITATIONS
1	Amine-weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumors. <i>NMR in Biomedicine</i> , 2023, 36, .	1.6	7
2	Characterization of cognitive function in survivors of diffuse gliomas using resting-state functional MRI (rs-fMRI). <i>Brain Imaging and Behavior</i> , 2022, 16, 239-251.	1.1	5
3	Imaging Advances for Central Nervous System Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 43-61.	0.9	4
4	Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors. <i>Neuro-Oncology</i> , 2022, 24, 1020-1028.	0.6	12
5	Radiomics for precision medicine in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2022, 156, 217-231.	1.4	22
6	Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI. <i>Scientific Reports</i> , 2022, 12, 1078.	1.6	5
7	Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease. <i>Frontiers in Oncology</i> , 2022, 12, 849993.	1.3	1
8	Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study. <i>Cancers</i> , 2022, 14, 2520.	1.7	2
9	Characterization of Cognitive Function in Survivors of Diffuse Gliomas Using Morphometric Correlation Networks. <i>Tomography</i> , 2022, 8, 1437-1452.	0.8	0
10	Voxelwise and Patientwise Correlation of <sup>18</sup> F-FDOPA PET, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient in Treatment-Naïve Diffuse Gliomas with Different Molecular Subtypes. <i>Journal of Nuclear Medicine</i> , 2021, 62, 319-325.	2.8	13
11	Relative oxygen extraction fraction (rOEF) MR imaging reveals higher hypoxia in human epidermal growth factor receptor (EGFR) amplified compared with non-amplified gliomas. <i>Neuroradiology</i> , 2021, 63, 857-868.	1.1	7
12	Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET. <i>Cancer Imaging</i> , 2021, 21, 27.	1.2	13
13	Using non-invasive neuroimaging to enhance the care, well-being and experimental outcomes of laboratory non-human primates (monkeys). <i>NeuroImage</i> , 2021, 228, 117667.	2.1	13
14	Preferential tumor localization in relation to <sup>18</sup> F-FDOPA uptake for lower-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2021, 152, 573-582.	1.4	2
15	Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden. <i>Annals of Nuclear Medicine</i> , 2021, 35, 1022-1029.	1.2	5
16	NIMG-74. RESPONSE ASSESSMENT AFTER DOSE-ESCALATED RADIOTHERAPY: IMAGING PROTOCOL OF A MULTICENTER PHASE III TRIAL ON INTRAOPERATIVE RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA (INTRAGO-II;ARO2016-1;AG-NRO-03). <i>Neuro-Oncology</i> , 2021, 23, vi146-vi146.	0.6	0
17	NIMG-41. PH-WEIGHTED MOLECULAR MRI AS AN EARLY BIOMARKER OF METABOLIC RESPONSE TO IDH INHIBITION IN IDH MUTANT GLIOMAS. <i>Neuro-Oncology</i> , 2021, 23, vi138-vi138.	0.6	0
18	Aerobic glycolytic imaging of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imaging. <i>NeuroImage: Clinical</i> , 2021, 32, 102882.	1.4	8

#	ARTICLE	IF	CITATIONS
19	NIMG-36. VISUALIZATION OF TUMOR HETEROGENEITY AND PREDICTION OF ISOCITRATE DEHYDROGENASE MUTATION STATUS FOR HUMAN GLIOMAS BY USING MULTIPARAMETRIC PHYSIOLOGIC AND METABOLIC MRI. <i>Neuro-Oncology</i> , 2021, 23, vi136-vi137.	0.6	0
20	NIMG-44. PROGNOSTIC VALUE OF PH- AND OXYGEN-SENSITIVE MRI IN GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2021, 23, vi138-vi139.	0.6	0
21	Longitudinal MRI findings in patients with newly diagnosed glioblastoma after intraoperative radiotherapy. <i>Journal of Neuroradiology</i> , 2020, 47, 166-173.	0.6	6
22	Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. <i>Neuro-Oncology</i> , 2020, 22, 17-30.	0.6	94
23	Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study. <i>Scientific Reports</i> , 2020, 10, 11922.	1.6	23
24	Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas. <i>Journal of Neuro-Oncology</i> , 2020, 149, 337-346.	1.4	5
25	Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma. <i>Scientific Reports</i> , 2020, 10, 14819.	1.6	13
26	Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden. <i>Neurosurgery</i> , 2020, 87, 931-938.	0.6	14
27	The MRI Features and Prognosis of Gliomas Associated With IDH1 Mutation: A Single Center Study in Southwest China. <i>Frontiers in Oncology</i> , 2020, 10, 852.	1.3	9
28	Diffusion MRI changes in the anterior subventricular zone following chemoradiation in glioblastoma with posterior ventricular involvement. <i>Journal of Neuro-Oncology</i> , 2020, 147, 643-652.	1.4	5
29	Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2020, 147, 135-145.	1.4	12
30	Glioblastoma Utilizes Fatty Acids and Ketone Bodies for Growth Allowing Progression during Ketogenic Diet Therapy. <i>IScience</i> , 2020, 23, 101453.	1.9	47
31	Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T. <i>American Journal of Neuroradiology</i> , 2019, 40, 979-986.	1.2	24
32	Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. <i>Neuro-Oncology</i> , 2019, 21, 1184-1196.	0.6	28
33	Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry. <i>Scientific Reports</i> , 2019, 9, 2846.	1.6	32
34	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. <i>Neuro-Oncology</i> , 2019, 21, 837-853.	0.6	66
35	pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 587-595.	1.4	28
36	PET imaging in patients with brain metastasis—report of the RANO/PET group. <i>Neuro-Oncology</i> , 2019, 21, 585-595.	0.6	139

#	ARTICLE	IF	CITATIONS
37	18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study. <i>Journal of Neuro-Oncology</i> , 2018, 139, 399-409.	1.4	32
38	Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo. <i>Neuro-Oncology</i> , 2018, 20, 1525-1535.	0.6	15
39	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1240-1250.	0.6	64
40	Simultaneous $^1\text{H}$ -sensitive and oxygen-sensitive $^3\text{T}_1$ using multi-echo amine proton chemical exchange saturation transfer spin-echo gradient echo echo-planar imaging ( $^3\text{T}_1$ -CEST-MAGE-EPI). <i>Magnetic Resonance in Medicine</i> , 2018, 80, 1962-1978.	1.9	38
41	Improved Spatiotemporal Resolution of Dynamic Susceptibility Contrast Perfusion MRI in Brain Tumors Using Simultaneous Multi-Slice Echo-Planar Imaging. <i>American Journal of Neuroradiology</i> , 2018, 39, 43-45.	1.2	15
42	Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1195-1203.	0.4	45
43	Conventional and advanced magnetic resonance imaging in patients with high-grade glioma. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 239-253.	0.4	63
44	Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 139, 651-659.	1.4	25
45	Gadolinium deposition within the paediatric brain: no increased intrinsic T1-weighted signal intensity within the dentate nucleus following the administration of a minimum of four doses of the macrocyclic agent gadobutrol. <i>European Radiology</i> , 2018, 28, 4882-4889.	2.3	12
46	Gadolinium Deposition within the Pediatric Brain: No Increased Intrinsic T1-Weighted Signal Intensity within the Dentate Nucleus following the Administration of a Minimum of 4 Doses of the Macrocyclic Agent Gadoteridol. <i>American Journal of Neuroradiology</i> , 2018, 39, 1604-1608.	1.2	16
47	Brain metastases: neuroimaging. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 149, 89-112.	1.0	123
48	Improving B0 Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation. <i>Tomography</i> , 2018, 4, 123-137.	0.8	16
49	Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 228-234.	0.6	77
50	The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. <i>NeuroImage: Clinical</i> , 2017, 13, 386-394.	1.4	101
51	Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade III diffuse gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 134, 177-188.	1.4	118
52	Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. <i>Journal of Neuro-Oncology</i> , 2017, 134, 495-504.	1.4	160
53	Evaluation of Magnetoparticles Conjugated with New Angiogenesis Peptides in Intracranial Glioma Tumors by MRI. <i>Applied Biochemistry and Biotechnology</i> , 2017, 183, 265-279.	1.4	13
54	Application of arterial spin labeling perfusion MRI to differentiate benign from malignant intracranial meningiomas. <i>European Journal of Radiology</i> , 2017, 97, 31-36.	1.2	42

#	ARTICLE	IF	CITATIONS
55	Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. <i>Clinical Cancer Research</i> , 2017, 23, 5745-5756.	3.2	53
56	Multiple calcifying pseudoneoplasms of the neuraxis (MCAPNON): Distinct entity, CAPNON variant, or old neurocysticercosis?. <i>Neuropathology</i> , 2017, 37, 233-240.	0.7	17
57	Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. <i>Neuro-Oncology</i> , 2017, 19, 89-98.	0.6	68
58	Molecular Imaging of Diffuse Low Grade Glioma. , 2017, , 173-195.		0
59	Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange. <i>American Journal of Neuroradiology</i> , 2016, 37, 1440-1446.	1.2	39
60	Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. <i>Neuro-Oncology</i> , 2016, 18, 1199-1208.	0.6	566
61	Two cases of rheumatoid meningitis. <i>Neuropathology</i> , 2016, 36, 93-102.	0.7	43
62	Dynamic Susceptibility Contrast MR Imaging in Glioma. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2016, 24, 649-670.	0.6	43
63	Simulation, phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3T. <i>NMR in Biomedicine</i> , 2016, 29, 1563-1576.	1.6	51
64	Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma. <i>Cancer</i> , 2016, 122, 1718-1727.	2.0	47
65	Blood-Labyrinth Barrier Permeability in Menière Disease and Idiopathic Sudden Sensorineural Hearing Loss: Findings on Delayed Postcontrast 3D-FLAIR MRI. <i>American Journal of Neuroradiology</i> , 2016, 37, 1903-1908.	1.2	67
66	Neuroimaging. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 27-50.	1.0	6
67	Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 1229-1237.	1.9	27
68	The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. <i>Clinical Cancer Research</i> , 2016, 22, 575-581.	3.2	62
69	Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 467-478.	0.6	67
70	Between-Scanner and Between-Visit Variation in Normal White Matter Apparent Diffusion Coefficient Values in the Setting of a Multi-Center Clinical Trial. <i>Clinical Neuroradiology</i> , 2016, 26, 423-430.	1.0	18
71	Modeling the efficacy of the extent of surgical resection in the setting of radiation therapy for glioblastoma. <i>Cancer Science</i> , 2016, 107, 1110-1116.	1.7	16
72	Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping. <i>NeuroImage: Clinical</i> , 2015, 9, 617-624.	1.4	23

#	ARTICLE	IF	CITATIONS
73	NIMG-24HIGH SPATIOTEMPORAL DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI USING MULTIBAND ECHOPLANAR IMAGING (MB-EPI). <i>Neuro-Oncology</i> , 2015, 17, v158.4-v159.	0.6	70
74	Evidence for rCBV as an early response marker following bevacizumab treatment. <i>Neuro-Oncology</i> , 2015, 17, 1539-1540.	0.6	2
75	A novel bicompartamental mathematical model of glioblastoma multiforme. <i>International Journal of Oncology</i> , 2015, 46, 825-832.	1.4	5
76	Patient-specific characterization of the invasiveness and proliferation of low-grade gliomas using serial MR imaging and a mathematical model of tumor growth. <i>Oncology Reports</i> , 2015, 33, 2883-2888.	1.2	5
77	Nitroxoline induces apoptosis and slows glioma growth in vivo. <i>Neuro-Oncology</i> , 2015, 17, 53-62.	0.6	41
78	From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?. <i>Neuro-Oncology</i> , 2015, 17, 1434-1444.	0.6	144
79	Predictive imaging marker of bevacizumab efficacy: perfusion MRI: TableÂ1.. <i>Neuro-Oncology</i> , 2015, 17, 1046-1047.	0.6	11
80	MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015, 122, 497-505.	1.4	37
81	Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas. <i>Molecular Imaging and Biology</i> , 2015, 17, 434-442.	1.3	28
82	Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI. <i>Clinical Cancer Research</i> , 2015, 21, 4373-4383.	3.2	27
83	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , The, 2015, 16, e534-e542.	5.1	582
84	pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. <i>Neuro-Oncology</i> , 2015, 17, 1514-1524.	0.6	96
85	Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. <i>Neuro-Oncology</i> , 2015, 17, 1188-98.	0.6	346
86	Standardized Brain Tumor Imaging Protocol for Clinical Trials. <i>American Journal of Neuroradiology</i> , 2015, 36, E65-E66.	1.2	4
87	Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma. <i>CNS Oncology</i> , 2015, 4, 247-256.	1.2	16
88	Genomics of Brain Tumor Imaging. <i>Neuroimaging Clinics of North America</i> , 2015, 25, 105-119.	0.5	33
89	Diffusion MRI Characteristics after Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma. <i>Tomography</i> , 2015, 1, 37-43.	0.8	12
90	Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. <i>Neuro-Oncology</i> , 2014, 16, 414-420.	0.6	82

#	ARTICLE	IF	CITATIONS
91	Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab. <i>Cancer Imaging</i> , 2014, 14, 31.	1.2	21
92	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). <i>Neuro-Oncology</i> , 2014, 16, vii36-vii47.	0.6	41
93	Emerging techniques and technologies in brain tumor imaging. <i>Neuro-Oncology</i> , 2014, 16, vii12-vii23.	0.6	41
94	BI-10 * pH-WEIGHTED MRI IN HUMAN GLIOMAS. <i>Neuro-Oncology</i> , 2014, 16, v25-v25.	0.6	0
95	Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial. <i>Radiology</i> , 2014, 271, 200-210.	3.6	150
96	Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 3550-3559.	3.2	115
97	Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. <i>Neuro-Oncology</i> , 2014, 16, 815-822.	0.6	49
98	Regional and Voxel-Wise Comparisons of Blood Flow Measurements Between Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) and Arterial Spin Labeling (ASL) in Brain Tumors. <i>Journal of Neuroimaging</i> , 2014, 24, 23-30.	1.0	45
99	Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI. <i>Journal of Neuro-Oncology</i> , 2014, 116, 373-379.	1.4	95
100	C-terminally truncated form of $\beta$ -crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma. <i>Journal of Neuro-Oncology</i> , 2014, 117, 53-65.	1.4	9
101	Facing the Future of Brain Tumor Clinical Research. <i>Clinical Cancer Research</i> , 2014, 20, 5591-5600.	3.2	4
102	Nonlinear distortion correction of diffusion MR images improves quantitative DTI measurements in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2014, 116, 551-558.	1.4	12
103	Short-interval estimation of proliferation rate using serial diffusion MRI predicts progression-free survival in newly diagnosed glioblastoma treated with radiochemotherapy. <i>Journal of Neuro-Oncology</i> , 2014, 116, 601-608.	1.4	6
104	Intraoperative mass spectrometry of tumor metabolites. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 10906-10907.	3.3	3
105	Isolated Choroid Plexus Granulomas: Initial Presentation of Neurosarcoidosis?. <i>Canadian Journal of Neurological Sciences</i> , 2014, 41, 112-114.	0.3	0
106	Validation of rano criteria: Contribution of T2/FLAIR assessment in patients with recurrent glioblastoma treated with bevacizumab.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2007-2007.	0.8	3
107	Pre- and post-contrast three-dimensional double inversion-recovery MRI in human glioblastoma. <i>Journal of Neuro-Oncology</i> , 2013, 112, 257-266.	1.4	13
108	Imaging biomarkers for antiangiogenic therapy in malignant gliomas. <i>CNS Oncology</i> , 2013, 2, 33-47.	1.2	17



#	ARTICLE	IF	CITATIONS
109	Ensemble segmentation for GBM brain tumors on MR images using confidence-based averaging. Medical Physics, 2013, 40, 093502.	1.6	12
110	Primary central nervous system histiocytic sarcoma presenting as a postradiation sarcoma: case report and literature review. Human Pathology, 2013, 44, 1177-1183.	1.1	34
111	PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors. PET Clinics, 2013, 8, 201-217.	1.5	8
112	Magnetic Resonance Imaging of Glioma in the Era of Antiangiogenic Therapy. PET Clinics, 2013, 8, 163-182.	1.5	4
113	Multi-delay multi-parametric arterial spin-labeled perfusion MRI in acute ischemic stroke – Comparison with dynamic susceptibility contrast enhanced perfusion imaging. NeuroImage: Clinical, 2013, 3, 1-7.	1.4	180
114	Functionalized Magnetoparticles in Visualization of Intracranial Tumors on MRI. Molecular Imaging and Biology, 2013, 15, 299-306.	1.3	4
115	Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro-Oncology, 2013, 15, 370-381.	0.6	97
116	Brainstem Gliomas. , 2013, 18, 237-242.		0
117	Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. Neuro-Oncology, 2013, 15, 626-634.	0.6	91
118	Reply:. American Journal of Neuroradiology, 2013, 34, E12-E12.	1.2	0
119	Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy. Neuro-Oncology, 2013, 15, 382-390.	0.6	38
120	Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. Neuro-Oncology, 2012, 14, 333-343.	0.6	74
121	<sup>18</sup> F-Deoxy- <sup>18</sup> F-Fluorothymidine PET and MRI for Early Survival Predictions in Patients with Recurrent Malignant Glioma Treated with Bevacizumab. Journal of Nuclear Medicine, 2012, 53, 29-36.	2.8	122
122	The Value of Arterial Spin-Labeled Perfusion Imaging in Acute Ischemic Stroke. Stroke, 2012, 43, 1018-1024.	1.0	151
123	<sup>18</sup> F-FDOPA and <sup>18</sup> F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro-Oncology, 2012, 14, 1079-1089.	0.6	99
124	Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. Neuro-Oncology, 2012, 14, 1465-1472.	0.6	35
125	Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: A radiographic study in 358 de novo human glioblastomas. NeuroImage, 2012, 59, 908-916.	2.1	128
126	Current Concepts in Brain Tumor Imaging. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 119-124.	1.8	3



#	ARTICLE	IF	CITATIONS
127	Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)â€MRI estimates of cerebral blood volume (CBV) in human gliomas. Journal of Magnetic Resonance Imaging, 2012, 35, 1472-1477.	1.9	68
128	Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. Journal of Neuro-Oncology, 2012, 108, 491-498.	1.4	149
129	Nonlinear registration of diffusionâ€weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab. Magnetic Resonance in Medicine, 2012, 67, 237-245.	1.9	36
130	Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. Journal of Neuro-Oncology, 2012, 106, 111-119.	1.4	67
131	Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. Journal of Neuro-Oncology, 2012, 107, 197-205.	1.4	280
132	High Order Diffusion Tensor Imaging in Human Glioblastoma. Academic Radiology, 2011, 18, 947-954.	1.3	10
133	Sampling-based ensemble segmentation against inter-operator variability. Proceedings of SPIE, 2011, , .	0.8	2
134	Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. Journal of Neuro-Oncology, 2011, 105, 91-101.	1.4	33
135	Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy. Current Neurology and Neuroscience Reports, 2011, 11, 336-344.	2.0	98
136	Evidence for Sequenced Molecular Evolution of <i>IDH1</i> Mutant Glioblastoma From a Distinct Cell of Origin. Journal of Clinical Oncology, 2011, 29, 4482-4490.	0.8	420
137	Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro-Oncology, 2011, 13, 401-409.	0.6	95
138	Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro-Oncology, 2011, 13, 1151-1161.	0.6	69
139	Confidence-based ensemble for GBM brain tumor segmentation. , 2011, , .		1
140	Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme. Journal of Clinical Oncology, 2011, 29, 142-148.	0.8	418
141	Insensitivity of visual assessment of hippocampal atrophy in familial Alzheimerâ€™s disease. Journal of Neurology, 2010, 257, 839-842.	1.8	17
142	Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. Journal of Neuro-Oncology, 2010, 96, 359-367.	1.4	86
143	Update and developments in the treatment of glioblastoma multiforme &ndash; focus on bevacizumab. Pharmacogenomics and Personalized Medicine, 2010, 3, 79.	0.4	4
144	CADrx for GBM Brain Tumors: Predicting Treatment Response from Changes in Diffusion-Weighted MRI. Algorithms, 2009, 2, 1350-1367.	1.2	8

#	ARTICLE	IF	CITATIONS
145	Engagement of Fusiform Cortex and Disengagement of Lateral Occipital Cortex in the Acquisition of Radiological Expertise. <i>Cerebral Cortex</i> , 2009, 19, 2746-2754.	1.6	94
146	Histogram-based classification with Gaussian mixture modeling for GBM tumor treatment response using ADC map. , 2009, , .		4
147	Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment. <i>Radiology</i> , 2009, 252, 182-189.	3.6	317
148	18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: Initial experience. <i>European Journal of Radiology</i> , 2009, 71, 242-248.	1.2	103
149	Cortical dysplasia with prominent Rosenthal fiber formation in a case of intractable pediatric epilepsy. <i>Human Pathology</i> , 2009, 40, 1200-1204.	1.1	6
150	Activity in the fusiform face area supports expert perception in radiologists and does not depend upon holistic processing of images. <i>Proceedings of SPIE</i> , 2009, , .	0.8	5
151	Time course of imaging changes of GBM during extended bevacizumab treatment. <i>Journal of Neuro-Oncology</i> , 2008, 88, 339-347.	1.4	101
152	Phase II Pilot Study of Bevacizumab in Combination with Temozolomide and Regional Radiation Therapy for Up-Front Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Interim Analysis of Safety and Tolerability. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1372-1380.	0.4	169
153	A methodology to integrate clinical data for the efficient assessment of brain-tumor patients. <i>Informatics for Health and Social Care</i> , 2008, 33, 55-68.	1.4	4
154	Safety of anticoagulation use and bevacizumab in patients with glioma. <i>Neuro-Oncology</i> , 2008, 10, 355-360.	0.6	85
155	Relationship between Gene Expression and Enhancement in Glioblastoma Multiforme: Exploratory DNA Microarray Analysis. <i>Radiology</i> , 2008, 249, 268-277.	3.6	146
156	3-T Contrast-Enhanced MR Angiography in Evaluation of Suspected Intracranial Aneurysm: Comparison with MDCT Angiography. <i>American Journal of Roentgenology</i> , 2008, 190, 389-395.	1.0	32
157	Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2. <i>Clinical Cancer Research</i> , 2007, 13, 2592-2598.	3.2	108
158	Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation With [ <sup>18</sup> F] Fluorothymidine Positron Emission Tomography: A Pilot Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 4714-4721.	0.8	400
159	Supraaortic Arteries: Contrast-enhanced MR Angiography at 3.0 Tâ€”Highly Accelerated Parallel Acquisition for Improved Spatial Resolution over an Extended Field of View. <i>Radiology</i> , 2007, 242, 600-609.	3.6	52
160	High Spatial-Resolution CE-MRA of the Carotid Circulation With Parallel Imaging. <i>Investigative Radiology</i> , 2006, 41, 391-399.	3.5	49
161	Contrast-enhanced MR angiography at 3T in the evaluation of intracranial aneurysms: a comparison with time-of-flight MR angiography. <i>American Journal of Neuroradiology</i> , 2006, 27, 2118-21.	1.2	44
162	18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. <i>Journal of Nuclear Medicine</i> , 2006, 47, 904-11.	2.8	293

#	ARTICLE	IF	CITATIONS
163	<title>Integration of HIS/RIS clinical document with PACS image studies for neuroradiology</title> . , 2005, , .		4
164	MR imaging correlates of survival in patients with high-grade gliomas. American Journal of Neuroradiology, 2005, 26, 2466-74.	1.2	315
165	Microtubule-Associated Protein Tau Is Hyperphosphorylated during Mitosis in the Human Neuroblastoma Cell Line SH-SY5Y. Experimental Neurology, 1994, 126, 185-194.	2.0	97
166	Phosphorylated Tau Epitope of Alzheimer's Disease Is Coupled to Axon Development in the Avian Central Nervous System. Experimental Neurology, 1993, 120, 106-113.	2.0	45
167	Transient expression of adhesion molecules during chick retinal development. Journal of Neurobiology, 1992, 23, 720-738.	3.7	3